Database : MEDLINE
Search on : erythema and nodosum [Words]
References found : 3681 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 369 go to page                         

  1 / 3681 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29516895
[Au] Autor:Gunawan H; Yogya Y; Hafinah R; Marsella R; Ermawaty D; Suwarsa O
[Ad] Address:Department of Dermatology and Venereology, Faculty of Medicine, Universitas Padjadjaran, Dr. Hasan Sadikin General Hospital, Bandung, Indonesia.
[Ti] Title:Reactive perforating leprosy, erythema multiforme-like reactions, sweet's syndrome-like reactions as atypical clinical manifestations of Type 2 leprosy reaction.
[So] Source:Int J Mycobacteriol;7(1):97-100, 2018 Jan-Mar.
[Is] ISSN:2212-554X
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:Type 2 leprosy reactions commonly known as erythema nodosum leprosum, but various clinical manifestations of type 2 leprosy reaction were exist. The highlight of this case series was to report various atypical clinical manifestations of type 2 leprosy reaction such as reactive perforating leprosy, erythema multiforme-like reaction, and sweet's syndrome (SS)-like reaction.
[Pt] Publication type:CASE REPORTS
[Em] Entry month:1803
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:In-Data-Review
[do] DOI:10.4103/ijmy.ijmy_186_17

  2 / 3681 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29272525
[Au] Autor:Mendes MA; de Carvalho DS; Amadeu TP; Silva BJA; Prata RBDS; da Silva CO; Ferreira H; Hacker MA; Nery JAC; Pinheiro RO; Sampaio EP; Sarno EN; Schmitz V
[Ad] Address:Laboratório de Hanseníase, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
[Ti] Title:Elevated Pentraxin-3 Concentrations in Patients With Leprosy: Potential Biomarker of Erythema Nodosum Leprosum.
[So] Source:J Infect Dis;216(12):1635-1643, 2017 Dec 19.
[Is] ISSN:1537-6613
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Background: Leprosy, the leading infectious cause of disability worldwide, remains a major public health challenge in the most severely affected countries despite the sharp decline in new cases in recent years. The search for biomarkers is essential to achieve a better understanding of the molecular and cellular mechanisms underlying the disease. Methods: Pentraxin-3 (PTX3) analyses of sera from 87 leprosy patients with or without reactions were conducted via enzyme-linked immunosorbent assay. In situ identification of PTX3 in skin lesion was confirmed by quantitative reverse-transcription polymerase chain reaction, immunohistochemistry, and immunofluorescence assays. Results: We found that PTX3 serum levels were higher in multibacillary patients when evaluated before the onset of acute erythema nodosum leprosum (ENL) and persistently elevated during reaction. Thalidomide treatment reduced PTX3 in the serum 7 days after starting treatment. In situ analyses have also demonstrated enhancement of PTX3 in ENL lesions and showed that treatment with thalidomide reduced its expression and the prominent neutrophilic infiltrate, a hallmark of the disease. Conclusions: In summary, our study provides in vivo evidence that PTX3 is enhanced during ENL but not in reversal reaction and provides a new molecular target in ENL pathogenesis.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:In-Data-Review
[do] DOI:10.1093/infdis/jix267

  3 / 3681 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29182760
[Au] Autor:Vavricka SR; Galván JA; Dawson H; Soltermann A; Biedermann L; Scharl M; Schoepfer AM; Rogler G; Prinz Vavricka MB; Terracciano L; Navarini A; Zlobec I; Lugli A; Greuter T
[Ad] Address:Division of Gastroenterology and Hepatology, University Hospital Zurich, Switzerland.
[Ti] Title:Expression Patterns of TNFα, MAdCAM1, and STAT3 in Intestinal and Skin Manifestations of Inflammatory Bowel Disease.
[So] Source:J Crohns Colitis;12(3):347-354, 2018 Feb 28.
[Is] ISSN:1876-4479
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Background: Pathogenesis of cutaneous extraintestinal manifestations [EIM] in inflammatory bowel disease [IBD] remains elusive. Efficacy of anti-TNF agents suggests TNF-dependent mechanisms. The role of other biologics, such as anti-integrins or JAK-inhibitors, is not yet clear. Methods: We performed immunohistochemistry for TNFα, NFκB, STAT1/STAT3, MAdCAM1, CD20/68, caspase 3/9, IFNγ, and Hsp-27/70 on 240 intestinal [55 controls, 185 IBD] and 64 skin biopsies [11 controls, 18 erythema nodosum [EN], 13 pyoderma gangenosum [PG], 22 psoriasis]. A semiquantitative score [0-100%] was used for evaluation. Results: TNFα was upregulated in intestinal biopsies from active Crohn`s disease [CD] vs controls [36.2 vs 12.1, p < 0.001], but not ulcerative colitis [UC: 17.9]. NFκB, however, was upregulated in intestinal biopsies from both active CD and UC [43.2 and 34.5 vs 21.8, p < 0.001 and p = 0.017, respectively]. TNFα and NFκB were overexpressed in skin biopsies from EN, PG, and psoriasis. No MAdCAM1 overexpression was seen in skin tissues, whereas it was upregulated in active UC vs controls [57.5 vs 35.4, p = 0.003]. STAT3 was overexpressed in the intestinal mucosa of active and non-active IBD, and a similar upregulation was seen in skin biopsies from EN [84.7 vs 22.3, p < 0.001] and PG [60.5 vs 22.3, p = 0.011], but not in psoriasis. Caspase 3 and CD68 overexpression in skin biopsies distinguished EN/PG from psoriasis and controls. Conclusions: Upregulation of TNFα/NFκB in EN and PG is compatible with the efficacy of anti-TNF in EIM management. Data on overexpressed STAT3, but not MAdCAM1, support a rationale for JAK-inhibitors in EN and PG, while questioning the role of vedolizumab.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1711
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:In-Process
[do] DOI:10.1093/ecco-jcc/jjx158

  4 / 3681 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 29317571
[Au] Autor:Pandhi D; Kulhari A
[Ad] Address:Department of Dermatology and STD University College of Medical Sciences (University of Delhi) and Guru Teg Bahadur Hospital, Delhi, India. deepikapandhi@rediffmail.com.
[Ti] Title:Erythema Nodosum Leprosum Necroticans.
[So] Source:Indian Pediatr;54(12):1071, 2017 12 15.
[Is] ISSN:0974-7559
[Cp] Country of publication:India
[La] Language:eng
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[St] Status:In-Process

  5 / 3681 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29499046
[Au] Autor:Negera E; Walker SL; Lemma T; Aseffa A; Lockwood DN; Dockrell HM
[Ad] Address:London School of Hygiene and Tropical Medicine, Faculty of Infectious Tropical Diseases, London, United Kingdom.
[Ti] Title:Complement C1q expression in Erythema nodosum leprosum.
[So] Source:PLoS Negl Trop Dis;12(3):e0006321, 2018 Mar 02.
[Is] ISSN:1935-2735
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Complement C1q is a soluble protein capable of initiating components of the classical pathway in host defence system. In earlier qualitative studies, C1q has been implicated in the pathogenesis of Erythema Nodosum Leprosum (ENL). However, little is known about the role of this complement in ENL reaction. In the present study we described the protein level of C1q production and its gene expression in the peripheral blood and skin biopsies in patients with ENL reaction and lepromatous leprosy (LL) patient controls before and after treatment. Thirty untreated patients with ENL reaction and 30 non-reactional LL patient controls were recruited at ALERT Hospital, Ethiopia. Peripheral blood and skin biopsies were obtained from each patient before and after treatment. The level of circulating C1q in the plasma was determined by enzyme-linked immunosorbent assay. The mRNA expression of the three C1q components, C1qA, C1qB, and C1qC in the peripheral blood and skin biopsies was determined by qPCR. Circulating C1q in the peripheral blood of untreated ENL patients was significantly decreased compared to LL patient controls. Untreated ENL patients had increased C1q gene expression in the peripheral blood compared to LL controls. Similarly, C1qA and C1qC gene expression were substantially increased in the skin biopsies of untreated ENL patients compared to LL controls. However, after treatment none of these genes show significant difference in both groups. In conclusion, while circulating C1q is inversely correlated with active ENL reactions, its gene expression is directly correlated with ENL. The decreased circulating C1q may suggest the utilization of C1q in immune-complex formation in these patients. Therefore, C1q could be a potential diagnostic marker for active ENL reactions as well as for monitoring ENL treatment.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180302
[Lr] Last revision date:180302
[St] Status:Publisher
[do] DOI:10.1371/journal.pntd.0006321

  6 / 3681 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29484571
[Au] Autor:Fleisher M; Marsal J; Lee SD; Frado LE; Parian A; Korelitz BI; Feagan BG
[Ad] Address:Borland-Groover Clinic, Jacksonville, FL, USA.
[Ti] Title:Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease.
[So] Source:Dig Dis Sci;, 2018 Feb 26.
[Is] ISSN:1573-2568
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: Approximately 15-20% of ulcerative colitis patients and 20-40% of those with Crohn's disease experience extraintestinal manifestations (EIMs) of their inflammatory bowel disease (IBD). Clinicians who treat IBD must manage EIMs affecting multiple organs that variably correlate with intestinal disease activity. Vedolizumab is a monoclonal antibody for the treatment of IBD with a gut-selective mechanism of action. AIMS: This report evaluates whether vedolizumab is an effective treatment of EIMs, given its gut-specific mechanism of action. METHODS: We report 8 case studies of patients with various EIMs, including pyoderma gangrenosum, peripheral arthralgia/arthritis, axial arthropathies, erythema nodosum, and uveitis, who received vedolizumab therapy. RESULTS: Vedolizumab therapy was effective for pyoderma gangrenosum in ulcerative colitis, uveitis, erythema nodosum, polyarticular arthropathy, and ankylosing spondylitis/sacroiliitis but did not provide sustained benefit for the treatment of pyoderma gangrenosum in a patient with Crohn's disease. CONCLUSIONS: These cases demonstrate the potential of vedolizumab as a treatment of EIMs in patients with IBD.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1802
[Cu] Class update date: 180227
[Lr] Last revision date:180227
[St] Status:Publisher
[do] DOI:10.1007/s10620-018-4971-1

  7 / 3681 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29474830
[Au] Autor:do Socorro Silva Costa P; Fraga LR; Kowalski TW; Daxbacher ELR; Schuler-Faccini L; Vianna FSL
[Ad] Address:Universidade Federal do Rio Grande do Sul, Av. Bento Gonçalves, 9500 - Prédio 43312 M, Porto Alegre, RS, Brazil; INAGEMP, Instituto Nacional de Genética Médica Populacional, Porto Alegre, Brazil, R. Ramiro Barcelos, 2350 - 21506 - Santa Cecilia, Porto Alegre , RS, Brazil; Universidade Federal do Mar
[Ti] Title:Erythema Nodosum Leprosum: Update and Challenges on the Treatment of a Neglected Condition.
[So] Source:Acta Trop;, 2018 Feb 20.
[Is] ISSN:1873-6254
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:Erythema Nodosum Leprosum (ENL) occurs due to the immunological complication of multibacillary leprosy and is characterized by painful nodules and systemic compromising. It is usually recurrent and/or chronic and has both physical and economic impact on the patient, being a very important cause of disability. In addition, ENL is a major health problem in countries where leprosy is endemic. Therefore, adequate control of this condition is important. The management of ENL aims to control acute inflammation and neuritis and prevent the onset of new episodes. However, all currently available treatment modalities have one or two drawbacks and are not effective for all patients. Corticosteroid is the anti-inflammatory of choice in ENL but may cause dependence, especially for chronic patients. Thalidomide has a rapid action but its use is limited due the teratogenicity and neurotoxicity. Clofazimine and pentoxifylline have slow action and have important adverse effects. Finally, there is no pattern or guidelines for treating these patients, becoming more difficult to evaluate and to control this condition. This review aims to show the main drugs used in the treatment of ENL and the challenges in the management of the reaction.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1802
[Cu] Class update date: 180223
[Lr] Last revision date:180223
[St] Status:Publisher

  8 / 3681 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29471416
[Au] Autor:Atienza-Mateo B; Calvo-Río V; Beltrán E; Martínez-Costa L; Valls-Pascual E; Hernández-Garfella M; Atanes A; Cordero-Coma M; Miquel Nolla J; Carrasco-Cubero C; Loricera J; González-Vela MC; Vegas-Revenga N; Fernández-Díaz C; Demetrio-Pablo R; Domínguez-Casas LC; Luis Martín-Varillas J; Palmou-Fontana N; Hernández JL; González-Gay MÁ; Blanco R
[Ad] Address:Rheumatology Division and Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Hospital Universitario Marques de Valdecilla, IDIVAL, University of Cantabria, Santander, Spain.
[Ti] Title:Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behçet's disease: multicentre retrospective study.
[So] Source:Rheumatology (Oxford);, 2018 Feb 19.
[Is] ISSN:1462-0332
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Objective: To assess the efficacy of tocilizumab (TCZ) in refractory uveitis of Behçet's disease (BD). Methods: Multicentre study of patients with BD-associated uveitis. Patients were refractory to conventional and biologic immunosuppressive drugs. The main outcome measures were intraocular inflammation, macular thickness, visual acuity and corticosteroid-sparing effects. Results: We studied 11 patients (7 men) (20 affected eyes); median age 35 years. Uveitis was bilateral in nine patients. The patterns of ocular involvement were panuveitis (n = 8, with retinal vasculitis in 4), anterior uveitis (n = 2) and posterior uveitis (n = 1). Cystoid macular oedema was present in seven patients. The clinical course was recurrent (n = 7) or chronic (n = 4). Before TCZ, patients had received systemic corticosteroids, conventional immunosuppressants and the following biologic agents: adalimumab (n = 8), infliximab (n = 4), canakimumab (n = 1), golimumab (n = 3), etanercept (n = 1). TCZ was used as monotherapy or combined with conventional immunosuppressants at 8 mg/kg/i.v./4 weeks (n = 10) or 162 mg/s.c./week (n = 1). At TCZ onset the following extraocular manifestations were present: oral and/or genital ulcers (n = 7), arthritis (n = 4), folliculitis/pseudofolliculitis (n = 4), erythema nodosum (n = 2), livedo reticularis (n = 1) and neurological involvement (n = 2). TCZ yielded rapid and maintained improvement in all ocular parameters of the patients, with complete remission in eight of them. However, this was not the case for the extraocular manifestations, since TCZ was only effective in three of them. After a mean (s.d.) follow-up of 9.5 (8.05) months, TCZ was withdrawn in two cases, due to a severe infusion reaction and arthritis impairment, respectively. Conclusion: TCZ could be a therapeutic option in patients with BD and refractory uveitis.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180222
[Lr] Last revision date:180222
[St] Status:Publisher
[do] DOI:10.1093/rheumatology/kex480

  9 / 3681 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29456153
[Au] Autor:Muñoz C; Restrepo-Escobar M; Martínez-Muñoz M; Echeverri A; Márquez J; Pinto LF
[Ad] Address:Sección de Reumatología, Departamento de Medicina Interna, Hospital Pablo Tobón Uribe, Medellín, Colombia.
[Ti] Title:Diferencias entre los pacientes con sarcoidosis con y sin compromiso articular atendidos durante quince años en un hospital de tercer nivel de complejidad. Differences Between Patients With Sarcoidosis With and Without Joint Involvement Treated for Fifteen Years in a Third Level Hospital.
[So] Source:Reumatol Clin;, 2018 Feb 15.
[Is] ISSN:1885-1398
[Cp] Country of publication:Spain
[La] Language:eng; spa
[Ab] Abstract:INTRODUCTION: Sarcoidosis is a complex disease of unknown etiology, with a variable course and highly different forms of presentation. Our objective was to characterize all our patients with sarcoidosis with emphasis on their clinical presentation and to establish differences between patients with sarcoidosis with and without joint involvement. METHODS: We reviewed the medical records of all patients with a diagnosis of sarcoidosis who were treated at the outpatient or inpatient services of the Pablo Tobón Uribe Hospital in Medellín, Colombia, from January 2002 to April 2017. RESULTS: We identified 22 patients with sarcoidosis. There were joint symptoms in 13 of them. All but one of the patients with sarcoidosis affecting the joints had concomitant skin involvement (92%), which was much less frequent in patients without joint involvement (22%) (odds ratio=4.2; P<.001). CONCLUSIONS: Patients with sarcoidosis who have joint involvement have a much higher frequency of concomitant skin involvement. The absence of cutaneous findings in a patient with joint symptoms decreases the likelihood of sarcoidosis.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180219
[Lr] Last revision date:180219
[St] Status:Publisher

  10 / 3681 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29453869
[Au] Autor:Coleman EL; Cowper SE; Stein SM; Leventhal JS
[Ad] Address:Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut.
[Ti] Title:Erythema Nodosum-like Eruption in the Setting of Sorafenib Therapy.
[So] Source:JAMA Dermatol;, 2018 Feb 16.
[Is] ISSN:2168-6084
[Cp] Country of publication:United States
[La] Language:eng
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180217
[Lr] Last revision date:180217
[St] Status:Publisher
[do] DOI:10.1001/jamadermatol.2017.5733


page 1 of 369 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information